SequelSEC

DYADIC INTERNATIONAL INC DYAI

Biological Products, (No Diagnostic Substances) · CIK 0001213809 · Fiscal year ends 1231

Revenue
$3.80M
Fiscal year ended 2026-06-30
Operating income
-$7.42M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

DYADIC INTERNATIONAL INC (DYAI) reported revenue of $3.80M and net income of -$7.62M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from DYADIC INTERNATIONAL INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

DYADIC INTERNATIONAL INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$3.80M
Cost of revenue$3.18M
Gross profit$617.62K
Operating income-$7.42M
Net income-$7.62M
Research & development$1.84M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$6.17M
Selling & marketingUnavailable

Balance

DYADIC INTERNATIONAL INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$1.43M
Total assets$6.54M
Current assets$6.41M
Total liabilities$8.92M
Current liabilities$3.88M
Total equity incl. NCI-$2.39M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$1.30M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$816.06K

Cash flow

DYADIC INTERNATIONAL INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$7.40M
Capital expendituresUnavailable
Investing cash flow$1.47M
Financing cash flowUnavailable
Net change in cash-$993.42K
Stock-based compensation$648.36K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

DYADIC INTERNATIONAL INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin16.2%
Operating margin-195.1%
FCF marginUnavailable
SBC / revenue17.1%
Current ratio1.65x
Revenue YoY growth-8.0%
Net margin-200.5%
R&D / revenue48.4%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DYAI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.